Galmed Pharmaceuticals (GLMD) FCF Payout Ratio (2013 - 2023)
Galmed Pharmaceuticals (GLMD) posted quarterly FCF Payout Ratio of 0.67 for Q1 2023, up 31.87% year-over-year from 0.51 in Q1 2022, and up 31.87% quarter-over-quarter from 0.98 in Q1 2022.
Galmed Pharmaceuticals (GLMD) FCF Payout Ratio (2013 - 2023) Analysis & Trends
Galmed Pharmaceuticals' FCF Payout Ratio history runs 10 years deep, the most recent figure standing at 0.67 for Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 0.17 |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 0.07 |
| 10 | Galmed Pharmaceuticals | 2.34 Mn | -9.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | -0.67 |
| Mar 31, 2022 | -0.98 |
| Mar 31, 2020 | -2.04 |
| Sep 30, 2019 | 1.94 |
| Jun 30, 2019 | 3.63 |
| Mar 31, 2019 | -9.78 |
| Sep 30, 2018 | -10.96 |
| Jun 30, 2018 | -2.43 |
| Mar 31, 2018 | -0.76 |
| Sep 30, 2017 | -0.30 |
| Jun 30, 2017 | -0.03 |
| Mar 31, 2017 | -0.43 |
| Sep 30, 2016 | -1.27 |
| Jun 30, 2016 | 0.05 |
| Mar 31, 2016 | -1.00 |
| Sep 30, 2015 | 1.27 |
| Jun 30, 2015 | -3.16 |
| Mar 31, 2015 | -1.04 |
| Sep 30, 2014 | 1.00 |
| Jun 30, 2014 | 1.01 |